MIRATI THERAPEUTICS INC's ticker is MRTX and the CUSIP is 60468T105. A total of 238 filers reported holding MIRATI THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.24 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $2,327,000 | +87.2% | 34,670 | +129.4% | 0.00% | +100.0% |
| Q1 2022 | $1,243,000 | -63.9% | 15,115 | -35.5% | 0.00% | -50.0% |
| Q4 2021 | $3,442,000 | -40.0% | 23,427 | -27.7% | 0.00% | -50.0% |
| Q3 2021 | $5,735,000 | +50.0% | 32,421 | +36.9% | 0.00% | +33.3% |
| Q2 2021 | $3,824,000 | -5.1% | 23,674 | +0.6% | 0.00% | -25.0% |
| Q1 2021 | $4,031,000 | -27.3% | 23,531 | -6.8% | 0.00% | -20.0% |
| Q4 2020 | $5,544,000 | +48.8% | 25,244 | +12.5% | 0.01% | +25.0% |
| Q3 2020 | $3,725,000 | +46.3% | 22,430 | +0.6% | 0.00% | +33.3% |
| Q2 2020 | $2,547,000 | +218.8% | 22,307 | +114.8% | 0.00% | +200.0% |
| Q1 2020 | $799,000 | -81.6% | 10,386 | -69.2% | 0.00% | -75.0% |
| Q4 2019 | $4,343,000 | +523.1% | 33,707 | +285.6% | 0.00% | +300.0% |
| Q3 2019 | $697,000 | -21.9% | 8,741 | +0.9% | 0.00% | 0.0% |
| Q2 2019 | $892,000 | -65.6% | 8,663 | -75.5% | 0.00% | -66.7% |
| Q1 2019 | $2,592,000 | – | 35,364 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aviva Holdings Ltd. | 3,135,966 | $116,595,216 | 81.37% |
| ORACLE INVESTMENT MANAGEMENT INC | 201,400 | $7,488,052 | 7.25% |
| Paradigm Biocapital Advisors LP | 1,396,779 | $51,932,243 | 4.92% |
| Octagon Capital Advisors LP | 750,000 | $27,885,000 | 4.01% |
| Boxer Capital, LLC | 2,000,000 | $74,360 | 3.65% |
| Artal Group S.A. | 1,537,709 | $57,172 | 3.40% |
| Avoro Capital Advisors LLC | 5,555,555 | $206,555,535 | 3.06% |
| RTW INVESTMENTS, LP | 3,643,114 | $135,450,979 | 2.82% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 244,000 | $9,071,920 | 2.53% |
| Kynam Capital Management, LP | 499,853 | $18,584,535 | 2.40% |